Results 171 to 180 of about 1,518 (207)

Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial

The Lancet, 2020
Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and reduced quality of life. There is no approved treatment for vitiligo repigmentation and current off-label therapies have limited efficacy, emphasising the need for improved treatment options.
David, Rosmarin, Amit G, Pandya, Mark, Lebwohl, Pearl, Grimes, Iltefat, Hamzavi, Alice B, Gottlieb, Kathleen, Butler, Fiona, Kuo, Kang, Sun, Tao, Ji, Michael D, Howell, John E, Harris   +11 more
openaire   +2 more sources

Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata

Journal of Drugs in Dermatology
Alopecia areata (AA) is a common autoimmune disorder. Although its pathogenesis is not fully understood, AA involves CD8 T cell-mediated destruction of the hair follicle. Several treatment options exist; however, there is minimal evidence in the pediatric population. Currently, there are no curative treatments for AA. The literature suggests that Janus
Yazmeen, Tembunde, Chesahna, Kindred
openaire   +2 more sources

OpzeluraTM (Ruxolitinib) Cream 1.5.

Skinmed
Ruxolitinib cream 1.5% was first approved by the US Food and Drug Administration (FDA) in 2011. Opzelura™ cream was introduced by Incyte Dermatology in 2021 for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients aged ≥12 years, whose clinical manifestations are not controlled
William, Abramovits, Akhil, Abraham, Kimberly Dawn, Vincent, Aditya K, Gupta   +3 more
openaire   +1 more source

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

New England Journal of Medicine, 2023
Janssen, Joséphine C, Mulder, Evalyn E A P, van der Veldt, Astrid A M   +2 more
openaire   +4 more sources

571 - Case series of topical 1.5% ruxolitinib cream for pediatric vitiligo

British Journal of Dermatology
Abstract Introduction/Background Pediatric Vitiligo affects 1.52% of 4-11-year-olds within the United States and 2.16% of 12-17-year-olds with non-segmental disease affecting 65% and 69% respectively (1).
Nanette Silverberg, Harry M Meister, Mark Lebwohl   +2 more
openaire   +1 more source

Vitiligo patients maintain re-pigmentation after ruxolitinib cream withdrawal

Medicom Conference Report AAD 2023, 2023
John Harris, Susanne Kammerer
openaire   +1 more source

25713 Ruxolitinib cream in the treatment of cutaneous lichen planus

Journal of the American Academy of Dermatology, 2021
Aaron R. Mangold, Caitlin M. Brumfiel, Meera H. Patel, Kevin J. Severson, Nan Zhang, Mark R. Pittelkow   +5 more
openaire   +1 more source

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

New England Journal of Medicine, 2021
Robert Zeiser, Nicola Polverelli, Ron Ram   +2 more
exaly  

194 Effect of ruxolitinib cream on biomarkers of atopic dermatitis

Journal of Investigative Dermatology, 2023
S. Smith, A. Volkova, Y. Estrada, J. Correa da Rosa, E. Saint-Cyr Proulx, H. Nawaz, P. Halden, E. Guttman-Yassky   +7 more
openaire   +1 more source

Biodegradable Zwitterionic Cream Gel for Effective Prevention of Postoperative Adhesion

Advanced Functional Materials, 2021
Ershuai Zhang, Jianhai Yang, Boyi Song
exaly